Clinical Trials Directory

Trials / Active Not Recruiting

Active Not RecruitingNCT03359954

Radiation Therapy Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Breast Cancer

PRECISE: Preoperative Radiotherapy to Elicit Critical Immune Stimulating Effects

Status
Active Not Recruiting
Phase
Phase 2
Study type
Interventional
Enrollment
25 (actual)
Sponsor
M.D. Anderson Cancer Center · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This phase II trial studies how well radiation therapy before surgery works in treating patients with hormone receptor positive, HER2 negative breast cancer. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving radiation therapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.

Detailed description

PRIMARY OBJECTIVES: I. To evaluate the change in percent tumor-infiltrating lymphocytes (TIL) as a continuous variable before and after preoperative boost radiotherapy (RT) in hormone receptor (HR)+/human epidermal growth factor receptor2 (HER2)- breast cancers. SECONDARY OBJECTIVES: I. To evaluate the safety of preoperative boost RT administered to patients with HR+/HER2- breast cancer. EXPLORATORY OBJECTIVES: * I. To assess the mechanisms of cell death induced by preoperative boost RT. * II. To assess immunologic and molecular responses to preoperative boost RT. * III. To assess the correlations between immune markers, cell death markers, and their changes during treatment. * IV. To determine if magnetic resonance imaging (MRI) can be used to predict breast tumor response to neoadjuvant radiation. OUTLINE: Patients undergo boost radiation therapy 6-8 days before breast surgery. After surgery, patients continue to receive standard of care radiation therapy. After completion of study treatment, patients are followed up at 6 months.

Conditions

Interventions

TypeNameDescription
RADIATIONRadiation TherapyUndergo radiation therapy
PROCEDURETherapeutic Conventional SurgeryUndergo breast surgery

Timeline

Start date
2017-11-16
Primary completion
2027-10-31
Completion
2027-10-31
First posted
2017-12-02
Last updated
2026-03-05

Locations

1 site across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT03359954. Inclusion in this directory is not an endorsement.